What changed: Recurrent or metastatic head and neck squamous cell carcinoma
Every dated change on the records linked to Recurrent or metastatic head and neck squamous cell carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Trial result7Milestone7This record1
September 2026 · 1
2026 · 1
2025 · 1
2023 · 2
- 2023Trial resultLow-dose nivolumab plus metronomic chemotherapy (Tata Memorial)Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial) reported
1-year OS 43.
- 2023MilestoneLow-dose nivolumab plus metronomic chemotherapy (Tata Memorial)Tata Memorial: low-dose nivolumab nearly triples one-year survival
A milestone in how this cancer is treated.
2020 · 2
- 2020Trial resultOral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial)Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial) reported
Median OS 7.
- 2020MilestoneOral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial)Tata Memorial: oral metronomic chemotherapy beats cisplatin
A milestone in how this cancer is treated.